5 Stocks Pushing The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 13,146 as of Friday, Dec. 14, 2012, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,344 issues advancing vs. 1,517 declining with 152 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. Top gainers within the industry include Community Health Systems ( CYH), up 1.6%, ResMed ( RMD), up 1.0% and Quest Diagnostics ( DGX), up 0.8%. On the negative front, top decliners within the industry include Centene Corporation ( CNC), down 8.5%, WellCare Health Plans ( WCG), down 5.9%, Molina Healthcare ( MOH), down 4.3% and Life Technologies ( LIFE), down 1.4%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Boston Scientific ( BSX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Boston Scientific is up $0.04 (0.7%) to $5.67 on light volume Thus far, 2.7 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 14.0 million shares. The stock has ranged in price between $5.66-$5.76 after having opened the day at $5.72 as compared to the previous trading day's close of $5.63.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $7.8 billion and is part of the health care sector. Shares are up 6.2% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Boston Scientific a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Boston Scientific Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways

Perils of Politics: Cramer's 'Mad Money' Recap (Monday 7/31/17)

These Stocks Are Ready to Reverse Course

Modi's Visit to Meet Trump Focuses Big Spotlight on the H-1B Visa Debate

Cramer: These Sectors Look Bullish (Part III)